This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

CorMedix Appoints Mark A. Klausner, M.D. As Chief Medical Officer

CorMedix Inc. (“CorMedix”) (NYSE Amex: CRMD), a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of cardiorenal disease, today announced the appointment of Mark A. Klausner, M.D. as Chief Medical Officer (“CMO”). Dr. Klausner has over 25 years of significant pharmaceutical experience spanning many functional and therapeutic areas, including extensive experience in the nephrology and cardiovascular therapeutic areas.

Dr. Klausner joins CorMedix from Nephrogenex, Inc. a developmental-stage biotechnology company, where he held the position of Chief Medical Officer since 2007. Dr. Klausner was responsible for the strategy and execution of Nephrogenex’s clinical trials and regulatory compliance, including its submissions and correspondence with the Food and Drug Administration (“FDA”). Previous to Nephrogenex, Dr. Klausner held various vice presidential roles at Johnson & Johnson (“J&J”) since 1990, in the areas of medical affairs, clinical R&D, and domestic and global drug safety and surveillance. Before joining J&J, Dr. Klausner held director positions at Wyeth Pharmaceuticals in the areas of cardiovascular clinical research and OTC clinical research since 1987. Prior to his pharmaceutical experience, Dr. Klausner was a member of a private practice, multi-specialty internal medicine group where he was one of two nephrologists with responsibilities for an outpatient dialysis center, in-hospital dialysis and nephrology consultations, and an office-based practice.

Dr. Klausner has been involved in several New Drug Applications and supplemental New Drug Applications. While at J&J, he was the lead company presenter at two public FDA Advisory Committee meetings resulting in new drug approvals. Dr. Klausner holds board certifications in nephrology and internal medicine. Dr. Klausner received his medical degree from Harvard Medical School. He completed his internship in Internal Medicine at Columbia Presbyterian Hospital in New York City and then returned to Harvard to complete his Internal Medicine residency and nephrology fellowship at Beth Israel Hospital in Boston. He has had extensive interactions with the nephrology community and regulatory bodies and has authored numerous publications in peer-reviewed medical journals.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $94.19 -1.04%
FB $118.06 0.54%
GOOG $695.70 0.48%
TSLA $222.56 -4.20%
YHOO $36.00 -0.03%


Chart of I:DJI
DOW 17,651.26 -99.65 -0.56%
S&P 500 2,051.12 -12.25 -0.59%
NASDAQ 4,725.6390 -37.5850 -0.79%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs